You are here

Palatability (Taste) of Oral Formulations of Bosutinib

Last updated on December 5, 2018

FOR MORE INFORMATION
Study Location
Pfizer Clinical Research Unit
Brussels, , B-1070 Belgium
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
CML
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Age and Sex:

1. Female participants of non-childbearing potential and/or male participants able to
father children must be 18 to 55 years of age, inclusive, at the time of signing the
informed consent document (ICD).

-Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female
(Section 10.4.2) participants.

Type of Participant and Disease Characteristics:

2. Male and female participants who are overtly healthy as determined by medical
evaluation including a detailed medical history, limited physical examination,
including blood pressure (BP) and pulse rate measurement, or clinical laboratory
tests.

3. Participants who are willing and able to comply with all scheduled visits, treatment
plan, laboratory tests, lifestyle considerations, and other study procedures.

Weight:

4. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).

Informed Consent:

5. Capable of giving signed informed consent as described in Appendix 1, which includes
compliance with the requirements and restrictions listed in the informed consent
document (ICD) and in this protocol.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Medical Conditions:

1. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at the time of dosing).

2. A history of hypersensitivity to the active compounds or to any inactive ingredients
(excipients) contained in the formulations.

3. Participants with conditions that affect their ability to taste - ie, dysgeusia,
respiratory infection, cold, etc.

4. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C;
positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core
antibody (HBcAb) or hepatitis C antibody (HCVAb). As an exception, a positive
hepatitis B surface antibody (HBsAb) as a result of participant vaccination is
permissible.

5. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the participant inappropriate for entry into
this study.

Prior/Concomitant Therapy:

6. Use of prescription or nonprescription drugs and dietary and herbal supplements within
7 days or 5 half lives (whichever is longer) prior to the first dose of
investigational product. (Refer to Section 6.5 for additional details).

Prior/Concurrent Clinical Study Experience:

7. Previous administration with an investigational drug within 30 days (or as determined
by the local requirement) or 5 half lives preceding the first dose of investigational
product used in this study (whichever is longer).

Diagnostic Assessments:

8. A positive urine drug test.

9. Use of tobacco-containing products.

10. Screening supine blood pressure (BP) 140 mm Hg (systolic) or 90 mm Hg (diastolic),
following at least 5 minutes of supine rest. If BP is 140 mm Hg (systolic) or 90 mm Hg
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP values
should be used to determine the participant's eligibility.

11. Baseline 12 lead electrocardiogram (ECG) that demonstrates clinically relevant
abnormalities that may affect participant safety or interpretation of study results
(eg, baseline corrected QT (QTc) interval >450 msec, complete left bundle branch block
[LBBB], signs of an acute or indeterminate age myocardial infarction, ST T interval
changes suggestive of myocardial ischemia, second or third degree atrioventricular
[AV] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline
uncorrected QT interval is >450 msec, this interval should be rate corrected using the
Fridericia method and the resulting QTcF should be used for decision making and
reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be
repeated 2 more times and the average of the 3 QTc or QRS values should be used to
determine the participant's eligibility. Computer interpreted ECGs should be overread
by a physician experienced in reading ECGs before excluding participants.

12. Participants with ANY of the following abnormalities in clinical laboratory tests at
screening, as assessed by the study specific laboratory and confirmed by a single
repeat test, if deemed necessary:

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level 1.5 ×
upper limit of normal (ULN);

- Total bilirubin level 1.5 × ULN; participants with a history of Gilbert's
syndrome may have direct bilirubin measured and would be eligible for this study
provided the direct bilirubin level is ULN.

Other Exclusions:

13. History of alcohol abuse or binge drinking and/or any other illicit drug use or
dependence within 6 months of Screening. Binge drinking is defined as a pattern of
consuming 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a
general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces
(240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).

14. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
within 60 days prior to dosing.

15. Unwilling or unable to comply with the criteria in the Lifestyle Considerations
section of this protocol.

16. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
Pfizer employees, including their family members, directly involved in the conduct of
the study.

17. Male participants with partners currently pregnant; male participants able to father
children who are unwilling or unable to use a highly effective method of contraception
as outlined in this protocol for the duration of the study and for at least 28 days
after the last dose of investigational product or longer based upon the compound's
half-life characteristics.

NCT03747679
Pfizer
Not yet recruiting
Palatability (Taste) of Oral Formulations of Bosutinib

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)
NCT01374139
All Genders
21+
Years
Singapore,
CML
NCT03747679
All Genders
18+
Years
Brussels,
Palatability (Taste) of Oral Formulations of Bosutinib
An Open-label, Non-randomized, Single-period Study In Healthy Adult Volunteers To Investigate The Palatability Of Select Oral Formulations Of Bosutinib (for Pediatric Use)
Healthy Adult Volunteer Taste Study of Oral Formulations of Bosutinib for Pediatric Use. This will be a single-blind, randomized, multiple-period (dosing over 4 days) study in healthy male and/or female participants. Approximately 8 participants will assess the sensory attributes of different powder for oral suspension (POS) formulations.

Taste evaluations for the formulations (Formulations A to N) in Sessions 1 to 4 each contains 4 periods. All the planned formulations in this study will have a bosutinib amount equal to 200 mg in each taste assessment. Session 1 consists of bosutinib POS, sorbitol base in water (A); bosutinib POS, mannitol base in water (B); and bosutinib capsules to be opened into water (C). Session 2 consists of bosutinib POS, mannitol base in low % (D) and in high % (E) sodium saccharine sweetener vehicles, respectively; bosutinib POS, mannitol base in low % (F) and high % (G) strawberry flavour vehicles, respectively. Session 3 consists of bosutinib capsules to be opened into low % (H) and high % (I) sodium saccharine sweetener vehicles, respectively; bosutinib capsules to be opened into low % (J) and high % (K) strawberry flavour vehicles, respectively. Session 4 consists of bosutinib capsules opened onto apple sauce (L); bosutinib capsules opened onto full fat natural yoghurt (M); and bosutinib capsules to be opened into water (N). Participants will be assigned to one of the treatment sequences available for each session. Except at session 4 for treatments L and M, each formulation will be presented to the participants in a blinded fashion.

Participants will be required to not swallow, rather to only swish the bosutinib containing liquid in their mouths for approximately 10 seconds, after which the liquid will be spat out. Each participant will record the sensory attributes at timed intervals of 0 (immediately after dosing), 5, 10 and 20 minutes after spitting using a Bosutinib Taste Assessment Questionnaire.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description:
This will be a single-blind, randomized, multiple-period (dosing over 4 days) study in healthy male and/or female participants. Approximately 8 participants will assess the sensory attributes of each of the formulation options using Bosutinib Taste Assessment Questionnaire

Masking: Single (Participant)
Masking Description:

single blind

Primary Purpose: Other

CML
  • Drug: 200 Mg capsules of bosutinib in Water solution
    200 mg (4X50) Capsules in water
  • Drug: bosunitib sorbitol
    200 Mg of bosutinib sorbitol solution
  • Drug: Bosutinib Mannitol
    Bosutinib mannitol solution
  • Drug: bosutinib in mannitol low sweet
    bosutinib in mannitol solution low sweet
  • Drug: bosutinib in mannitol high sweet
    bosutinib in mannitol high sweet
  • Drug: bosutinib taste low flavour
    bosutinib solution low flavour
  • Drug: bosutinib high flavour
    bosutinib solution high flavour
  • Drug: bosutinib capsules in applesauce
    Bosutinib capsules in applesauce
  • Drug: Bosutinib capsules in yogurt
    bosutinib capsules in yogurt
  • Drug: bosutinib capsules in water
    sham comparator, bosutinb in water retest
  • Drug: Bosutinib capsules in low sweet
    bosutinib capsules in low sweet
  • Drug: bosutinib capsules high sweet
    Bosutinib capsules high sweet
  • Drug: bosutinib capsules low flavour
    Bosutinib capsules low flavour
  • Drug: bosutinib capsules high flavour
    bosutinib capsules in high flavour
  • Experimental: A- Bosutinib in water
    200 Mg of bosutinib (50 mg capsule x4) in Water solution
    Intervention: Drug: 200 Mg capsules of bosutinib in Water solution
  • Experimental: B- bosutinib in sorbitol
    200 Mg of bosutinib sorbitol base in water solution
    Intervention: Drug: bosunitib sorbitol
  • Experimental: C- - bosutinib mannitol
    200 Mg of bosutinib powder mannitol base in water solution
    Intervention: Drug: Bosutinib Mannitol
  • Experimental: D - bosutinib in mannitol low sweet
    200 Mg of bosutinib mannitol low sweet solution
    Intervention: Drug: bosutinib in mannitol low sweet
  • Experimental: E- - bosutinib in mannitol high sweet
    200 Mg of bosutinib High % sweet mannitol solution
    Intervention: Drug: bosutinib in mannitol high sweet
  • Experimental: F- - bosutinib low flavour
    Taste assessment of 200 Mg of bosutinib low % Flavour
    Intervention: Drug: bosutinib taste low flavour
  • Experimental: G- bosutinib high flavour
    Taste assessment of 200 Mg of bosutinib high percentage of flavor in water
    Intervention: Drug: bosutinib high flavour
  • Experimental: H- - bosutinib capsules in low sweet
    Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet
    Intervention: Drug: Bosutinib capsules in low sweet
  • Experimental: I - bosutinib capsules high sweet
    200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener
    Intervention: Drug: bosutinib capsules high sweet
  • Experimental: J- - bosutinib capsules low flavour
    Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution
    Intervention: Drug: bosutinib capsules low flavour
  • Experimental: K - bosutinib capsules high flavour
    Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour
    Intervention: Drug: bosutinib capsules high flavour
  • Experimental: L - bosutinib capsules applesauce
    200 Mg of bosutinib (50 mg x 4 capsules) in applesauce
    Intervention: Drug: bosutinib capsules in applesauce
  • Experimental: M - bosutinib capsules full fat yougurt
    200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt
    Intervention: Drug: Bosutinib capsules in yogurt
  • Experimental: N - bosutinib capsules in water (retest)
    200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)
    Intervention: Drug: bosutinib capsules in water
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
8
Same as current
December 20, 2018
December 20, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Age and Sex:

  1. Female participants of non-childbearing potential and/or male participants able to father children must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD).

    -Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.

    Type of Participant and Disease Characteristics:

  2. Male and female participants who are overtly healthy as determined by medical evaluation including a detailed medical history, limited physical examination, including blood pressure (BP) and pulse rate measurement, or clinical laboratory tests.
  3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

    Weight:

  4. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).

    Informed Consent:

  5. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.

Exclusion Criteria:

Medical Conditions:

  1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. A history of hypersensitivity to the active compounds or to any inactive ingredients (excipients) contained in the formulations.
  3. Participants with conditions that affect their ability to taste - ie, dysgeusia, respiratory infection, cold, etc.
  4. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody (HCVAb). As an exception, a positive hepatitis B surface antibody (HBsAb) as a result of participant vaccination is permissible.
  5. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.

    Prior/Concomitant Therapy:

  6. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product. (Refer to Section 6.5 for additional details).

    Prior/Concurrent Clinical Study Experience:

  7. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product used in this study (whichever is longer).

    Diagnostic Assessments:

  8. A positive urine drug test.
  9. Use of tobacco-containing products.
  10. Screening supine blood pressure (BP) 140 mm Hg (systolic) or 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is 140 mm Hg (systolic) or 90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  11. Baseline 12 lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline corrected QT (QTc) interval >450 msec, complete left bundle branch block [LBBB], signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
  12. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level 1.5 × upper limit of normal (ULN);
    • Total bilirubin level 1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ULN.

    Other Exclusions:

  13. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of consuming 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
  14. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  15. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
  16. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
  17. Male participants with partners currently pregnant; male participants able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product or longer based upon the compound's half-life characteristics.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Not Provided
 
 
NCT03747679
B1871057
2018-002346-37 ( EudraCT Number )
BCHILD TASTE ( Other Identifier: Alias Study Number )
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now